NRAS tumor mutations are associated with reduced odds of dermatologic adverse events in patients with metastatic melanoma receiving immune checkpoint inhibitors

被引：0
|
作者：
Chang, Michael S. [1 ,2 ]
Said, Jordan T. [1 ,2 ]
Akama-Garren, Elliot H. [1 ,2 ]
Trepanowski, Nicole [2 ,3 ]
Bui, Ai-Tram N. [1 ,2 ]
Giobbie-Hurder, Anita [4 ]
Leboeuf, Nicole R. [1 ,2 ,5 ]
Hartman, Rebecca I. [1 ,2 ,6 ]
机构：
[1] Harvard Med Sch, BOSTON, MA USA
[2] Brigham & Womens Hosp, Dept Dermatol, 221 Longwood Ave, Boston, MA 02215 USA
[3] Boston Univ, Sch Med, Boston, MA USA
[4] Dana Farber Canc Inst, Dept Data Sci, Div Biostat, Boston, MA USA
[5] Dana Farber Brigham & Womens Canc Ctr, Ctr Cutaneous Oncol, Boston, MA USA
[6] Vet Integrated Serv Network VISN 1, Dept Dermatol, Jamaica Plain, MA USA
来源：
JAAD INTERNATIONAL | 2025年 / 18卷
基金：
美国国家卫生研究院;
关键词：
anti-PDL-1; atezolizumab; avelumab; cemiplimab; dAE; durvalumab; ICI; ipilimumab; melanoma; mutation; nivolumab; NRAS; pembrolizumab;
D O I：
10.1016/j.jdin.2024.11.004
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
[No abstract available]
引用
收藏
页码：165 / 167
页数：3
相关论文
共 50 条
  • [1] Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic Melanoma
    Woelffer, Marcus
    Battke, Florian
    Schulze, Martin
    Feldhahn, Magdalena
    Flatz, Lukas
    Martus, Peter
    Forschner, Andrea
    CANCERS, 2022, 14 (02)
  • [2] Management of skin adverse events associated with immune checkpoint inhibitors in patients with melanoma: A nursing perspective
    Thebeau, Melissa
    Rubin, Krista
    Hofmann, Matthias
    Grimm, Julia
    Weinstein, Alyona
    Choi, Jennifer N.
    JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS, 2017, 29 (05) : 294 - 303
  • [3] Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma
    Kassi, Eva
    Angelousi, Anna
    Asonitis, Nikolaos
    Diamantopoulos, Panagiotis
    Anastasopoulou, Amalia
    Papaxoinis, George
    Kokkinos, Michalis
    Giovanopoulos, Ilias
    Kyriakakis, Georgios
    Petychaki, Fotini
    Savelli, Akrivi
    Benopoulou, Olga
    Gogas, Helen
    CANCER MEDICINE, 2019, 8 (15): : 6585 - 6594
  • [4] Patterns of neurological adverse events among a retrospective cohort of patients receiving immune checkpoint inhibitors
    Hunting, John C.
    Faucheux, Andrew T.
    Price, Sarah N.
    Elko, Catherine A.
    Quattlebaum, Alexander
    Bloomer, Chance
    Olson, Eric
    Petty, William J.
    Lycan Jr, Thomas W.
    IMMUNOTHERAPY, 2024, 16 (06) : 381 - 390
  • [5] Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach
    Heilbroner, Samuel Peter
    Few, Reed
    Mueller, Judith
    Chalwa, Jitesh
    Charest, Francois
    Suryadevara, Somasekhar
    Kratt, Christine
    Gomez-Caminero, Andres
    Dreyfus, Brian
    Neilan, Tomas G.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (10)
  • [6] Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
    Das, Satya
    Johnson, Douglas B.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01)
  • [7] Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma
    Karhapaa, Hanna
    Makela, Siru
    Lauren, Hanna
    Jaakkola, Marjut
    Schalin-Jantti, Camilla
    Hernberg, Micaela
    ENDOCRINE CONNECTIONS, 2022, 11 (02)
  • [8] Histologic subtype of cutaneous immune-related adverse events predicts overall survival in patients receiving immune checkpoint inhibitors
    Hirotsu, Kelsey E.
    Scott, Madeleine K. D.
    Marquez, Cesar
    Tran, Anhthy T.
    Rieger, Kerri E.
    Novoa, Roberto A.
    Robinson, William H.
    Kwong, Bernice Y.
    Zaba, Lisa C.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : 651 - 653
  • [9] Assessment of Variables Related to the Risk of Severe Adverse Events in Cutaneous Melanoma Patients Treated with Immune Checkpoint Inhibitors
    Trichkova, Kremena Petrova
    Gortler, Franziska
    Bjorge, Line
    Schuster, Cornelia
    CANCERS, 2024, 16 (02)
  • [10] Corticosteroids for the management of immune-related adverse events in patients receiving checkpoint inhibitors
    Williams, Kiersten J.
    Grauer, Dennis W.
    Henry, David W.
    Rockey, Michelle L.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (03) : 544 - 550
12345